Serge Clotaire Billong1,2,3, Joseph Fokam1,3,4,5, Calixte Ida Penda6,7, Ernest Anaba Mvilongo2, Raoul Fodjo2, Arlette Messeh2, Jean de Dieu Anoubissie2, Cyprien Kegne2, Gildas Nguekam8, Yannick Aimé Batamack2, Edson Joan Billong9, Pamela Reine Moutapam2, Alexis Ndjolo1,4, Leonard Bonono2, Jean Bosco Elat2,10, Anne Cécilé Zoung-Kanyi Bissek1,3,8. 1. Département de Santé Publique, Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun. 2. Groupe Technique Central, Comité Nationale de Lutte Contre le SIDA, Yaoundé, Cameroun. 3. Groupe de Travail National pour la Prévention et la Surveillance de la Pharmaco-résistance du VIH, Ministère de la Santé Publique, Yaoundé, Cameroun. 4. Centre International de Référence Chantal BIYA pour la Recherche sur la Prévention et la Prise en Charge du VIH/SIDA, Yaoundé, Cameroun. 5. Faculty of Health Sciences, University of Buea, Buea, Cameroon. 6. Hôpital de Jour, Hôpital Laquintinie de Douala, Douala, Cameroun. 7. Faculté de Médecine et des Sciences Pharmaceutiques, Université de Douala, Douala, Cameroun. 8. Division de la Recherche Opérationnelle en Santé, Ministère de la Santé Publique, Yaoundé, Cameroun. 9. Faculté de Médecine, Université d'Antananarivo, Antananarivo, Madagascar. 10. George Town University, Yaoundé, Cameroun.
Abstract
INTRODUCTION: since the launch of the "Treatment for All in Cameroon" strategy in 2015, an acceleration plan for antiretroviral (ARV) therapy in Cameroon was implemented, with remarkable progresses. These efforts were accompanied by the risk of developing HIV drug resistance. Then, the World Health Organization (WHO) proposed surveillance of early warning indicators (IAP) for HIV drug resistance. The purpose of this study was to assess the national HIV Drug Resistance Early Warning Indicators (EWI) in Cameroon. METHODS: we conducted a retrospective study in the ten regions of Cameroon in December 2017 to evaluate the six EWIs recommended by the WHO in 68 randomly selected HIV care sites. The reporting period ranged from July 2016 to June 2017. RESULTS: national scores were: drug withdrawal within the estimated time frame (EWI1): 66%; retention on antiretroviral therapy 12 months after treatment initiation (EWI2): 66%; stock-out of antiretroviral drugs over a 12-month period (EWI3): 53%; viral load testing coverage (CV) (EWI4): 10%; coverage suppression after 12 months of antiretroviral therapy (EWI5): 73% and practices for ARV drug delivery (EWI6): (100%). Regional scores were similar. CONCLUSION: the evaluation of EWI in Cameroon is limited and requires urgent interventions, primarily viral load testing coverage, optimal ARVs management and patient´s adherence. Copyright: Serge Clotaire Billong et al.
INTRODUCTION: since the launch of the "Treatment for All in Cameroon" strategy in 2015, an acceleration plan for antiretroviral (ARV) therapy in Cameroon was implemented, with remarkable progresses. These efforts were accompanied by the risk of developing HIV drug resistance. Then, the World Health Organization (WHO) proposed surveillance of early warning indicators (IAP) for HIV drug resistance. The purpose of this study was to assess the national HIV Drug Resistance Early Warning Indicators (EWI) in Cameroon. METHODS: we conducted a retrospective study in the ten regions of Cameroon in December 2017 to evaluate the six EWIs recommended by the WHO in 68 randomly selected HIV care sites. The reporting period ranged from July 2016 to June 2017. RESULTS: national scores were: drug withdrawal within the estimated time frame (EWI1): 66%; retention on antiretroviral therapy 12 months after treatment initiation (EWI2): 66%; stock-out of antiretroviral drugs over a 12-month period (EWI3): 53%; viral load testing coverage (CV) (EWI4): 10%; coverage suppression after 12 months of antiretroviral therapy (EWI5): 73% and practices for ARV drug delivery (EWI6): (100%). Regional scores were similar. CONCLUSION: the evaluation of EWI in Cameroon is limited and requires urgent interventions, primarily viral load testing coverage, optimal ARVs management and patient´s adherence. Copyright: Serge Clotaire Billong et al.
Entities:
Keywords:
Cameroon; Early warning indicators; HIV drug resistance
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Serge C Billong; Joseph Fokam; Armand S Nkwescheu; Etienne Kembou; Pascal Milenge; Zephirin Tsomo; Grace Ngute Dion; Avelin F Aghokeng; Eitel N Mpoudi; Peter M Ndumbe; Vittorio Colizzi; Jean B Elat Nfetam Journal: PLoS One Date: 2012-05-17 Impact factor: 3.240
Authors: Kouadio Jean Yao; Néto Florence Damey; Diby Jean Paul Konan; Joseph Aka; Sandrine Aka-Konan; Alex Ani; Marguerite Te Bonle; Dinard Kouassi Journal: Pan Afr Med J Date: 2016-09-30
Authors: Joseph Fokam; Serge C Billong; Anne C Z K Bissek; Etienne Kembou; Pascal Milenge; Ibile Abessouguie; Armand S Nkwescheu; Zephirin Tsomo; Avelin F Aghokeng; Grace D Ngute; Peter M Ndumbe; Vittorio Colizzi; Jean B N Elat Journal: BMC Public Health Date: 2013-04-08 Impact factor: 3.295
Authors: Joseph Fokam; Jean-Bosco N Elat; Serge C Billong; Etienne Kembou; Armand S Nkwescheu; Nicolas M Obam; André Essiane; Judith N Torimiro; Gatien K Ekanmian; Alexis Ndjolo; Koulla S Shiro; Anne C Z-K Bissek Journal: PLoS One Date: 2015-06-17 Impact factor: 3.240
Authors: Anna Jonas; Victor Sumbi; Samson Mwinga; Michael DeKlerk; Francina Tjituka; Scott Penney; Michael R Jordan; Tiruneh Desta; Alice M Tang; Steven Y Hong Journal: PLoS One Date: 2014-07-02 Impact factor: 3.240